Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial

Lancet
Reena KhannaREACT Study Investigators

Abstract

Conventional management of Crohn's disease features incremental use of therapies. However, early combined immunosuppression (ECI), with a TNF antagonist and antimetabolite might be a more effective strategy. We compared the efficacy of ECI with that of conventional management for treatment of Crohn's disease. In this open-label cluster randomised controlled trial (Randomised Evaluation of an Algorithm for Crohn's Treatment, REACT), we included community gastroenterology practices from Belgium and Canada that were willing to be assigned to either of the study groups, participate in all aspects of the study, and provide data on up to 60 patients with Crohn's disease. These practices were randomly assigned (1:1) to either ECI or conventional management. The computer-generated randomisation was minimised by country and practice size. Up to 60 consecutive adult patients were assessed within practices. Patients who were aged 18 years or older; documented to have Crohn's disease; able to speak or understand English, French, or Dutch; able to access a telephone; and able to provide written informed consent were followed up for 2 years. The primary outcome was the proportion of patients in corticosteroid-free remission (Harvey-Bradshaw ...Continue Reading

References

Jun 6, 1996·Health Policy·R Brooks
Nov 20, 2002·European Journal of Gastroenterology & Hepatology·Hans-Helmut KönigReiner Leidl
Apr 9, 2005·BMJ : British Medical Journal·Douglas G Altman, J Martin Bland
Apr 10, 2007·Digestive Diseases and Sciences·Meaghan DonovanRaymond K Cross
Nov 27, 2008·World Journal of Gastroenterology : WJG·Selwyn Odes
Mar 7, 2009·Inflammatory Bowel Diseases·Meaghan St CharlesRaymond K Cross
Dec 3, 2010·Journal of Crohn's & Colitis·A DignassUNKNOWN European Crohn's and Colitis Organisation (ECCO)
Jan 29, 2011·PharmacoEconomics·Keith Bodger

❮ Previous
Next ❯

Citations

Oct 17, 2015·Expert Review of Gastroenterology & Hepatology·Krisztina Barbara GecsePéter László Lakatos
Dec 19, 2015·Expert Review of Clinical Pharmacology·A S StrikM Löwenberg
Jul 28, 2015·Expert Opinion on Biological Therapy·Mahmoud H Mosli, Brian G Feagan
Jan 23, 2016·Expert Opinion on Drug Safety·Konstantinos PapamichaelLaurent Peyrin-Biroulet
Mar 28, 2016·Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·Pierre-Olivier BlotièreFrançois Alla
Sep 8, 2015·Lancet·Siddharth Singh, Edward V Loftus
Apr 5, 2016·Expert Review of Gastroenterology & Hepatology·Guillaume Pineton de ChambrunLaurent Peyrin-Biroulet
Jun 11, 2016·Journal of Crohn's & Colitis·Joana TorresJean-Frédéric Colombel
Jun 23, 2016·Expert Opinion on Biological Therapy·Lieven PouillonLaurent Peyrin-Biroulet
Oct 30, 2016·Journal of Crohn's & Colitis·Gionata Fiorino, Silvio Danese
Nov 4, 2016·The American Journal of Gastroenterology·Stephan R TarganPaul Klekotka
Jul 28, 2016·Current Gastroenterology Reports·Parambir S Dulai, William J Sandborn
Feb 26, 2016·Lancet·Ioan MilosevicUNKNOWN COMPare project team
Feb 26, 2016·Lancet·Hans H HerfarthMichael D Kappelman
Feb 26, 2016·Lancet·Reena Khanna, UNKNOWN REACT investigators
Oct 19, 2016·Digestive Diseases and Sciences·Gionata Fiorino, Silvio Danese
Nov 9, 2016·MMW Fortschritte der Medizin·Torsten Kucharzik
Oct 11, 2016·Gastroenterology·Jean-Frederic ColombelLaurent Peyrin-Biroulet
Feb 2, 2017·Nature Reviews. Gastroenterology & Hepatology·Markus F Neurath
Jan 31, 2017·Expert Opinion on Biological Therapy·Simon Hirschmann, Markus F Neurath
Mar 2, 2017·Alimentary Pharmacology & Therapeutics·P B AllenL Peyrin-Biroulet
Feb 28, 2017·Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association·Laura E TargownikCharles N Bernstein
May 4, 2017·Current Opinion in Gastroenterology·Pablo OliveraLaurent Peyrin-Biroulet
Jun 15, 2017·Expert Opinion on Drug Metabolism & Toxicology·Lukasz KwapiszBrian Feagan
Jul 15, 2017·Alimentary Pharmacology & Therapeutics·C H Seow, R Panaccione
Apr 4, 2017·Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association·Robert BattatWaqqas Afif
Jul 29, 2017·Alimentary Pharmacology & Therapeutics·M EberhardsonO Olén
Oct 14, 2017·Journal of Crohn's & Colitis·Leonardo GuizzettiBrian G Feagan
Sep 22, 2017·International Journal of Molecular Sciences·Grainne HolleranFranco Scaldaferri
Nov 1, 2016·Gut·Corey A SiegelLaurent Peyrin-Biroulet
Mar 24, 2018·Colorectal Disease : the Official Journal of the Association of Coloproctology of Great Britain and Ireland·M J LeeS R Brown
Dec 7, 2016·Gastroenterology Nursing : the Official Journal of the Society of Gastroenterology Nurses and Associates·Sharon Dudley-Brown
Oct 14, 2017·Alimentary Pharmacology & Therapeutics·C MartineauUNKNOWN Goli-Crohn Study Group
Oct 12, 2017·Nature Reviews. Gastroenterology & Hepatology·Bo Shen
Nov 18, 2017·Therapeutic Advances in Gastroenterology·Patrick B AllenLaurent Peyrin-Biroulet
May 23, 2018·Inflammatory Bowel Diseases·Claire Liefferinckx, Denis Franchimont
Aug 1, 2018·Alimentary Pharmacology & Therapeutics·Paulo G KotzeRemo Panaccione
Aug 6, 2018·Current Gastroenterology Reports·Siddharth Singh

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atrophic Gastritis

Atrophic Gastritis is a process where gastric glandular cells are lost and replaced with firbous tissues, as a result of chronic inflammation. Learn more about Atrophic Gastritis here.

Ataxias (MDS)

Ataxia is a neurological condition characterized by lack of voluntary coordination of muscle movements including loss of coordination, balance, and speech. Discover the latest research on ataxia here.

Ataxia

Ataxia is a neurological condition characterized by lack of voluntary coordination of muscle movements including loss of coordination, balance, and speech. Discover the latest research on ataxia here.